[go: up one dir, main page]

AR011592A1 - Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped - Google Patents

Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped

Info

Publication number
AR011592A1
AR011592A1 ARP980100406A ARP980100406A AR011592A1 AR 011592 A1 AR011592 A1 AR 011592A1 AR P980100406 A ARP980100406 A AR P980100406A AR P980100406 A ARP980100406 A AR P980100406A AR 011592 A1 AR011592 A1 AR 011592A1
Authority
AR
Argentina
Prior art keywords
guest
induce
creation
maintenance
hiv virus
Prior art date
Application number
ARP980100406A
Other languages
English (en)
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Publication of AR011592A1 publication Critical patent/AR011592A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proponen métodos y composiciones para el uso de una forma mutante nueva de E.coli lábil al calor enterotoxina que perdio su toxicidad peroretuvo su actividad inmunologica. Esta enterotoxina se usa en combinacion con un antígeno no relacionado para lograr una respuesta inmune aumentada a dichoantígeno cuando se administra como parte de una preparacion de vacuna.
ARP980100406A 1997-01-29 1998-01-29 Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped AR011592A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79069197A 1997-01-29 1997-01-29

Publications (1)

Publication Number Publication Date
AR011592A1 true AR011592A1 (es) 2000-08-30

Family

ID=25151481

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100406A AR011592A1 (es) 1997-01-29 1998-01-29 Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped

Country Status (5)

Country Link
AR (1) AR011592A1 (es)
AU (1) AU6044598A (es)
CO (1) CO4810235A1 (es)
WO (1) WO1998032461A1 (es)
ZA (1) ZA98738B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANT
CN1297316C (zh) 2001-06-07 2007-01-31 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IT1253009B (it) * 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini

Also Published As

Publication number Publication date
ZA98738B (en) 1998-08-04
AU6044598A (en) 1998-08-18
CO4810235A1 (es) 1999-06-30
WO1998032461A1 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DE60024112D1 (de) Influenzavirus-impfstoffzusammensetzung
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
ES2186809T3 (es) Composiciones de vacunas para administracion intranasal, comprendiendo chitosana y su uso.
DK0814836T3 (da) Vaccineadjuvanser
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
NO20015073D0 (no) Vaksiner
ATE410183T1 (de) Verbesserte adjuvant zusammensetzungen auf basis von saponin und damit zusammenhängende methoden
MX9101077A (es) Composicion para vacuna que comprende un conjugado de proteina-polisacarido bacteriano y un adyuvante de alquilo de cadena larga
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
ZA936629B (en) Potentiation of immunogenic response
EA199900069A1 (ru) Вакцинная композиция против малярии
BR0010418B1 (pt) microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo.
NO20015074D0 (no) Nye sammensetninger
ES2140837T3 (es) Adyuvante a base de saponina de madera de panama y formulacion de vacuna que lo contiene.
ES2530510T3 (es) Constructos peptídicos sintéticos para el diagnóstico y tratamiento de periodontitis asociada con Porphyromonas gingivalis
TW340873B (en) Chicken anaemia agent vaccine
AR011592A1 (es) Metodo de creacion, o mantenimiento o para inducir una inmuno respuesta protectora o adaptativa a un virus hiv en un huesped
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
ES2046246T3 (es) Composicion terapeutica para combatir el sida.
AR010568A1 (es) Polipeptido, composicion de vacuna, uso del polipeptido en la fabricacion de una composicion, y metodo para producir en un mamifero una respuestainmuno-protectora contra la infeccion de helicobacter pylori
DK0858345T3 (da) Anvendelse af muteiner af vildtypecytokiner som immunogener
BR0013574A (pt) Antìgeno vacina de moraxella
DE60120840D1 (de) Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit